Vertex Pharmaceuticals (VRTX) EBITDA (2009 - 2026)

Vertex Pharmaceuticals' EBITDA history runs 18 years deep, the most recent figure standing at $1.1 billion for Q1 2026.

• In Q1 2026, EBITDA rose 80.62% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $4.7 billion (up 730.65% YoY), while the FY2025 annual figure was $4.2 billion, up 1891.88% from the prior year.
• EBITDA for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
• The five-year high for EBITDA was $1.2 billion in Q4 2025, with the low at -$3.5 billion in Q2 2024.
• The 5-year median for EBITDA is $1.0 billion (2022), against an average of $777.5 million.
• The sharpest annual moves came in 2022 and 2024: EBITDA surged 3019.0% in 2022, then sank 442.43% in 2024.
• Vertex Pharmaceuticals' EBITDA stood at $1.0 billion in 2022, then dropped by 4.35% to $988.5 million in 2023, then increased by 3.79% to $1.0 billion in 2024, then climbed by 17.53% to $1.2 billion in 2025, then slipped by 5.62% to $1.1 billion in 2026.
• Business Quant data shows VRTX's EBITDA at $1.1 billion in Q1 2026, $1.2 billion in Q4 2025, and $1.2 billion in Q3 2025.